Epigenetic downregulation of the retinoic acid receptor-β2 gene in breast cancer

Journal of Mammary Gland Biology and Neoplasia

Volumn 6, Issue 2, 2001, Pages 193-201

  Widschwendter, Martin ^a   Berger, Jennifer ^a   Müller, Hannes M ^a   Zeimet, Alain G ^a   Marth, Christian ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Breast cancer; Carcinogenesis; Chemoprevention; Epigenetic; Methylation; Retinoic acid receptor 2

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALITRETINOIN; BISULFITE; BRCA1 PROTEIN; FENRETINIDE; HISTONE DEACETYLASE INHIBITOR; RALOXIFENE; RETINOIC ACID; RETINOIC ACID RECEPTOR BETA; RETINOID; SODIUM PHENYLBUTYRATE; STAT1 PROTEIN; TAMOXIFEN; UNCLASSIFIED DRUG; ENZYME INHIBITOR; MESSENGER RNA; RETINOIC ACID RECEPTOR;

APOPTOSIS; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CLINICAL TRIAL; DEMETHYLATION; DNA METHYLATION; DRUG POTENTIATION; EPIGENETICS; GENE EXPRESSION REGULATION; GENE SEQUENCE; GENE SILENCING; HUMAN; MYELODYSPLASTIC SYNDROME; NONHUMAN; POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; REVIEW; SYSTEMATIC REVIEW; TUMOR SUPPRESSOR GENE; BREAST TUMOR; CELL CULTURE; CHEMOPROPHYLAXIS; DOWN REGULATION; DRUG EFFECT; FEMALE; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE;

BASE SEQUENCE; BREAST NEOPLASMS; CHEMOPREVENTION; DNA METHYLATION; DOWN-REGULATION; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR SEQUENCE DATA; RECEPTORS, RETINOIC ACID; RNA, MESSENGER; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 0035321924     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011360724350     Document Type: Review

References (68)

1. C. López-Otín and E. P. Diamandis (1998). Breast and prostate cancer: An analysis of common epidemiological, genetic, and biochemical features. Endocrinol. Rev. 19:365-396.
2. M. B. Sporn and D. L. Newton (1979). Chemoprevention of cancer with retinoids. Fed. Proc. 38:2528-2534.
3. W. Ki Hong, S. M. Lippman, W. N. Hittelmann, and R. Lotan (1995). Retinoid chemoprevention of aerodigestive cancer: From basic research to the clinic. Clin. Cancer Res. 1:677-686.
4. U. Pastorino, M. Infante, M. Maioli, G. Chiesa, M. Buyse, P. Firket, et al. (1993). Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J. Clin. Oncol. 11:1216-1222.
5. U. Veronesi, G. De Palo, E. Marubini. A. Costa, F. Formelli, L. Mariani, A. Decensi, T. Camerini, M. R. Del Turco, M. G. Di Mauro, M. G. Muraca, M. Del Vecchio, C. Pinto, G. D'Aiuto, C. Boni, T. Campa, A. Magni, R. Miceli, M. Perloff, W. F. Malone, and M. B. Sporn (1999). Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J. Natl. Cancer. Inst. 91: 847-1856.
6. R. C. Moon, D. L. McCormick, and R. G. Mehta (1983). Inhibition of carcinogenesis by retinoids. Cancer Res. 43:2469s-2475s.
7. M. A. Anzano, S. W. Byers, J. M. Smith, C. W. Peer, L. T. Mullen, C. C. Brown, A. B. Roberts, and M. B. Sporn (1994). Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res. 54:4614-4617.
8. M. A. Anzano, C. W. Peer, J. M. Smith, L. T. Mullen, M. W. Shrader, D. L. Logsdon, C. L. Driver, C. C. Brown, A. B. Roberts, and M. B. Sporn (1996). Chemoprevention of mammary carcinogenesis in the rat: Combined use of raloxifene and 9-cis-retinoic acid. J. Natl. Cancer Inst. 88:123-125.
9. B. S. Herbert, A. C. Wright, C. M. Passons, W. E. Wright, I. U. Ali, L. Kopelovich, and J. W. Shay (2001) Effects of chemopreventive and antitelomerase agents on the spontaneous immortalization of breast epithelial cells. J. Natl. Cancer Inst. 93:39-45.
10. M. Widschwendter, G. Daxenbichler, O. Dapunt, and C. Marth (1995). Effects of retinoic acid and γ-interferon on expression of retinoic acid receptor and cellular retinoic acid-binding protein in breast cancer cells. Cancer Res. 55:2135-2139.
11. A. N. Fanjul, H. Bouterfa, M. Dawson, and M. Pfahl (1996). Potential role for retinoic acid receptor-γ in the inhibition of breast cancer cells by selective retinoids and interferons. Cancer Res. 56: 571-1577.
12. M. Widschwendter, G. Daxenbichler, Z. Culig, S. Michel, A. G. Zeimet, M. G. Mörtl, A. Widschwendter, and C. Marth (1997). Activity of retinoic acid receptor-γ selectively binding retinoids alone and in combination with Interferon-γ in breast cancer cell lines. Int. J. Cancer 71:497-504.
13. M. Widschwendter, A. Widschwendter, T. Welte, G. Daxenbichler, A. G. Zeimet, A. Bergant, J. Berger, J. P. Peyrat, C. Marth, and W. Doppler (1999). Retinoic acid modulates prolactin receptor expression and prolactin-induced Stat-5 activation in breast cancer cells in vitro. Brit. J. Cancer 79:204-210.
14. H. P. Ciolino, T. T. Y. Wang, and N. Sathyamoorthy (2000). Inhibition of aromatase activity and expression in MCF-7 cells by the chemopreventive retinoid N-(4-hydroxy-phenyl)-retinamide. Brit. J. Cancer. 83:333-337.
15. P. Chambon (1996). A decade of molecular biology of retinoic acid receptors. FASEB J. 10:940-954.
16. H. de The, A. Marchio, P. Tiollais, and A. Dejean (1989). Differential expression and ligand regulation of the retinoic acid receptor α and β genes. EMBO J. 8:429-433.
17. B. M. van der Leede, G. E. Folkers, F. A. E. Kruyt, and P. T. van der Saag (1992). Genomic organization of the human retinoic acid receptor β2. Biochem. Biophys. Res. Commun. 188:695-702.
18. B. Hoffmann, J. M. Lehmann, X. K. Zhang, T. Hermann, M. Husmann, G. Graupner, and M. Pfahl (1990). A retinoic acid receptor-specific element controls the retinoic acid receptor-β promoter. Mol. Endocrinol. 4:1727-1736.
19. X. K. Zhang, Y. Liu, M. O. Lee, and M. Pfahl (1994). A specific defect in the retinoic acid receptor associated with human lung cancer cell lines. Cancer Res. 54:5663-5669.
20. B. Houle, C. Rochette-Egly, and W. E. C. Bradley (1993). Tumor-suppressive effect of the retinoic acid receptor β in human epidermoid lung cancer cells. Proc. Natl. Acad. Sci. U.S.A. 90:985-989.
21. X.-C. Xu, J. Y. Ro, J. S. Lee, D. M. Shin, W. K. Hong, and R. Lotan (1994). Differential expression of nuclear retinoid receptors in normal, premalignant and malignant head and neck tissues. Cancer Res. 54:3580-3587.
22. H. Qiu, W. Zhang, A. K. El-Naggar, S. M. Lippman, P. Lin, R. Lotan, and X.-C. Xu (1999). Loss of retinoic acid receptor-β expression is an early event during esophageal carcinogenesis. Amer. J. Pathol. 155: 519-1523.
23. X.-C. Xu, X. Liu, E. Tahara, S. M. Lippman, and R. Lotan (1999). Expression and up-regulation of retinoic acid receptor-β is associated with retinoid sensitivity and colony formation in esophageal cancer cell lines. Cancer Res. 59:2477-2483.
24. A. L. Sabichi, D. T. Hendricks, M. A. Bober, and M. J. Birrer (1998). Retinoic acid receptor β expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-Hyroxyphenyl) Retinamide. J. Natl. Cancer. Inst. 90:597-605.
25. Y. Lotan, X-C. Xu, M. Shalev, R. Lotan, R. Williams, T. M. Wheeler, T. C. Thompson, and D. Kadmon (2000). Differential expression of nuclear retinoid receptors in normal and malignant prostates. J. Clin. Oncol. 18:116-121.
26. K. Swisshelm, K. Ryan, X. Lee, H. C. Tsou, M. Peacocke, and R. Sager (1994). Down-regulation of retinoic acid receptor β in mammary carcinoma cell lines and its up-regulation in senescing normal mammary epithelial cells. Cell Growth Differ. 5:133-141.
27. Y. Liu, M. Lee, H-G. Wang, Y. Li, Y. Hashimoto, M. Klaus, et al. (1996). Retinoic acid receptor β mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells. Mol. Cell. Biol. 16:1138-1149.
28. X. Lee, S. P. Si, H. C. Tsou, and M. Peacocke (1995). Cellular aging and transformation suppression: A role for retinoic acid receptor β2. Exp. Cell Res. 218:296-304.
29. T. N. Faria, C. Mendelsohn, P. Chambon, and L. J. Gudas (1999). The targeted disruption of both alleles of RARβ(2) in F9 cells results in the loss of retinoic acid-associated growth arrest. J. Biol. Chem. 274:26783-26788.
30. J. Berard, F. Laboune, M. Mukuna, S. Masse, R. Kothary, and W. E. C. Bradley (1996). Lung tumors in mice expressing an antisense RARβ2 transgene. FASEB J. 10:1091-1097.
31. M. Widschwendter, J. Berger, G. Daxenbichler, E. Müller-Holzner, A. Widschwendter, A. Mayr, C. Marth, and A. G. Zeimet (1997). Loss of retinoic acid receptor β expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer. Cancer Res. 57:4158-4161.
32. X-C. Xu, N. Sneige, X. Liu, R. Nandagiri, J. J. Lee, F. Lukmanji, G. Hortobagyi, S. M. Lippman, K. Dhingra, and R. Lotan (1997). Progressive decrease in nuclear retinoic acid receptor β messenger RNA level during breast carcinogenesis. Cancer Res. 57:4992-4996.
33. K. M. Sommer, L. I. Chen, P. M. Treuting, L. T. Smith, and K. Swisshelm (1999). Elevated retinoic acid receptor β4 protein in human breast tumor cells with nuclear and cytoplasmic localization. Proc. Natl. Acad. Sci. U.S.A. 96:8651-8656.
34. T. Ouchi, S. M. Lee, M. Ouchi, S. A. Aaronson, and C. M. Horvath (2000). Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFN-γ target genes. Proc. Natl. Acad. Sci. U.S.A. 97:5208-5213.
35. V. Kolla, D. J. Lindner, W. Xiao, E. C. Borden, and D. V. Kalvakolanu (1996). Modulation of interferon (IFN)-inducible gene expression by retinoic acid. Up-regulation of STAT1 protein in IFN-unresponsive cells. J. Biol. Chem. 271:10508-10514.
36. Y. Shang, C. R. Baumrucker, and M. H. Green (1999). The induction and activation of STAT1 by all-trans-retinoic acid are mediated by RARβ signaling pathways in breast cancer cells. Oncogene 18: 725-6732.
37. R. K. Srivastava, A. R. Srivastava, Y. S. Cho-Chung, and D. L. Longo (1999). Synergistic effects of retinoic acid and 8-chloro-adenosine 3′,5′-cyclic monophosphate on the regulation of retinoic acid receptor β and apoptosis: Involvement of mitochondria. Clin. Cancer Res. 5:1892-1904.
38. X.-C. Xu, J. S. Lee, J. J. Lee, R. C. Morice, X. Liu, S. M. Lippman, W. K. Hong, and R. Lotan (1999). Nuclear retinoic acid receptor-β in bronchial epithelium of smokers before and during chemoprevention. J. Natl. Cancer Inst. 91:1317-1321.
39. R. Lotan, X. C. Xu, S. M. Lippman, J. Y. Ro, J. S. Lee, J. J. Lee, and W. K. Hong (1995). Suppression of retinoic acid receptor-β in premalignant oral lesions and its up-regulation by isotretinoin. N. Engl. J. Med. 332:1405-1410.
40. F. D. Urnov and A. P. Wolffe (2001). Above and within genome: Epigenetics past and present. J. Mam. Gland Biol. Neoplasia, 6(2):xX-xx.
41. L. M. Mielnicki, H. L. Asch, and B. B. Asch (2001). Genes, chromatin, and breast cancer: An epigenetic tale. J. Mam. Gland Biol. Neoplasia 6(2):169-182.
42. S. Côté and R. L. Momparler (1997). Activation of the retinoic acid receptor-β gene by 5-aza-2′-deoxycytidine in human DLD-1 colon carcinoma cells. Anti-Cancer Drugs 8:56-61.
43. M. Widschwendter, J. Berger, M. Hermann, H. M. Müller, A. Amberger, M. Zeschnigk, A. Widschwendter, B. Abendstein, A. G. Zeimet, G. Daxenbichler, and C. Marth (2000). Methylation and silencing of the retinoic acid receptor-β2 gene in breast cancer. J. Natl. Cancer Inst. 92:826-832.
44. E. E. Cameron, K. E. Bachman, S. Myöhänen, J. G. Herman, and S. B. Baylin (1999). Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21:103-107.
45. A. Arapshian, Y. S. Kuppumbatti, and R. Mira-y-Lopez (2000). Methylation of conserved CpG sites neighboring the β retinoic acid response element may mediate retinoic acid receptor β gene silencing in MCF-7 breast cancer cells. Oncogene 19:4066-4070.
46. M. L. Gonzalgo and P. A. Jones (1997). Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SnuPE). Nucleic Acids Res. 25:2529-2531.
47. C. Salem, G. Liang, Y. C. Tsai, J. Coulter, M. A. Knowles, A.-C. Feng, S. Groshen, P. W. Nichols, and P. A. Jones (2000). Progressive increases in de novo methylation of CpG islands in bladder cancer. Cancer Res. 60:2473-2476.
48. G. Liang, K. D. Robertson, C. Talmadge, J. Sumegi, and P. A. Jones (2000). The gene for a novel transmembrane protein containing epidermal growth factor and follistatin domains is frequently hypermethylated in human tumor cells. Cancer Res. 60:4907-4912.
49. G. Deng, Y. Lu, G. Zlotnikov, A. D. Thor, and H. S. Smith (1996). Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science 274:2057-2059.
50. P. A. Jones and P. W. Laird (1999). Cancer epigenetics comes of age. Nat. Genet. 21:163-167.
51. Q. Wu, Y. Li, R. Liu, A. Agadir, M. O. Lee, Y. Liu, and X. Zhang (1997). Modulation of retinoic acid sensitivity in lung cancer cells through dynamic balance of orphan receptors nur77 and COUP-TF and their heterodimerization. EMBO J. 16:1656-1669.
52. S. M. Sirchia, A. T. Ferguson, E. Sironi, S. Subramanyan, R. Orlandi, S. Sukumar, and N. Sacchi (2000). Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor β2 promoter in breast cancer cells. Oncogene 19:1556-1563.
53. Q. Yang, I. Mori, L. Shan, M. Nakamura, Y. Nakamura, H. Utsunomiya, G. Yoshimura, T. Suzuma, T. Tamaki, T. Umemura, T. Sakurai, and K. Kakudo (2001). Biallelic inactivation of retinoic acid receptor β2 gene by epigenetic change in breast cancer. Amer. J. Pathol. 158: 99-303.
54. A. K. Virmani, A. Rathi, S. Zochbauer-Muller, N. Sacchi, Y. Fukuyama, D. Bryant, A. Maitra, S. Heda, K. M. Fong, F. Thunnissen, J. D. Minna, and A. F. Gazdar (2000). Promoter methylation and silencing of the retinoic acid receptor-β gene in lung carcinomas. J. Natl. Cancer Inst. 92:1303-1307.
55. P. W. Laird, L. Jackson-Grusby, A. Fazeli, S. L. Dickinson, W. E. Jung, E. Li, R. A. Weinberg, and R. Jaenisch (1995). Suppression of intestinal neoplasia by DNA hypomethylation. Cell 81:197-205.
56. L. E. Lantry, Z. Zhang, K. A. Crist, Y. Wang, G. J. Kelloff, R. A. Lubet, and M. You (1999). 5-Aza-2′-deoxycytidine is chemopreventive in a 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone-induced primary mouse lung tumor model. Carcinogenesis 20:343-346.
57. S. B. Baylin and J. G. Herman (2000). DNA hypermethylation in tumorigenesis: Epigenetics joins genetics. Trends Genet. 16: 68-174.
58. M. Toyota and J. P. Issa (2000). The role of DNA hypermethylation in human neoplasia. Electrophoresis 21:329-333.
59. V. Bovenzi, N. L. Le, S. Cote, D, Sinnett, L. F. Momparler, and R. L. Momparler (1999). DNA methylation of retinoic acid receptor β in breast cancer and possible therapeutic role of 5-aza-2′-deoxycytidine. Anticancer Drugs 10:471-476.
60. P. Wijermans, M. Lubbert, G. Verhoef, A. Bosly, C. Ravoet, M. Andre, and A. Ferrant (2000). Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicentre phase II study in elderly patients. 2000. J. Clin. Oncol. 18:956-962.
61. S. Minucci, V. Horn, N. Bhattacharyya, V. Russanova, V. V. Ogryzko, L. Gabriele, B. H. Howard, and K. Ozato (1997). A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells. Proc. Natl. Acad. Sci. U.S.A. 94:11295-11300.
62. W. A. Palmisano, K. K. Divine, G. Saccomanno, F. D. Gilliland, S. B. Baylin, J. G. Herman, and S. A. Belinsky (2000). Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 60:5954-5958.
63. J. M. Silva, G. Dominguez, J. M. Garcia, R. Gonzalez, M. J. Villanueva, F. Navarro, M. Provencio, S. San-Martin, P. Espana, and F. Bonilla (1999). Presence of tumor DNA in plasma of breast cancer patients: Clinicopathological correlations. Cancer Res. 59:3251-3256.
64. INK4a gene in plasma DNA of breast cancer patients. Brit. J. Cancer 80:1262-1264.
65. M. Esteller, M. Sanchez-Cespedes, R. Rosell, D. Sidransky, S. B. Baylin, and J. G. Herman (1999). Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from nonsmall cell lung cancer patients. Cancer Res. 59:67-70.
66. I. H. N. Wong, Y. M. D. Lo, J. Zhang, C-T. Liew, M. H. L. Ng, N. Wong, P. B. S. Lai, W. Y. Lau, N. M. Hjelm, and P. J. Johnson (1999). Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res. 59:71-73.
67. X. Chen, H. Bonnefoi, S. Diebold-Berger, J. Lyautey, C. Lederrey, E. Faltin-Traub, M. Stroun, and P. Anker (1999). Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer. Clin. Cancer. Res. 5:2297-2303.
68. M. B. Sporn (2000). Retinoids and demethylating agents-looking for partners. J. Natl. Cancer Inst. 92:780-781.